Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2013

Open Access 01-11-2013 | Meeting abstract

PW02-021 - SAA1 is the strongest predictor of AA in TRAPS

Authors: L Obici, HJ Lachmann, I Touitou, G Palladini, S Donadei, M Pasotti, L Cantarini, K Gerhold, A Meini, N Toplak, P Woo, A Martini, G Merlini, M Gattorno

Published in: Pediatric Rheumatology | Special Issue 1/2013

Login to get access

Excerpt

AA amyloidosis is the most severe complication of hereditary autoinflammatory diseases. In TRAPS it has been reported to occur in approximately 25% of patients in the absence of an effective treatment. However, susceptibility to AA is difficult to predict. Identification of key risk factors affecting the development of AA would improve the clinical management of TRAPS patients, by allowing a more tailored treatment approach. …
Metadata
Title
PW02-021 - SAA1 is the strongest predictor of AA in TRAPS
Authors
L Obici
HJ Lachmann
I Touitou
G Palladini
S Donadei
M Pasotti
L Cantarini
K Gerhold
A Meini
N Toplak
P Woo
A Martini
G Merlini
M Gattorno
Publication date
01-11-2013
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue Special Issue 1/2013
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/1546-0096-11-S1-A161

Other articles of this Special Issue 1/2013

Pediatric Rheumatology 1/2013 Go to the issue

Meeting abstract

P02-033 - CAPS diagnosis and treatment in an Israeli family

Meeting abstract

PW03-014 - TLR4 and MEFV variants are Behçet's risk factors

Meeting abstract

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized

Meeting abstract

PW02-036 - Thermosensitive CA2+ assay innate immune cells

Meeting abstract

OR11-006 - A mutation in NLRP1A causes autoinflammation

Meeting abstract

P03-028 – Spectacular efficiency of isotretinoin in small doses in the sebopsoriasis treatment